Tags

Type your tag names separated by a space and hit enter

COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations.
Int J Lab Hematol. 2021 Jul; 43 Suppl 1:29-35.IJ

Abstract

Vascular endothelial injury is a hallmark of acute infection at both the microvascular and macrovascular levels. The hallmark of SARS-CoV-2 infection is the current COVID-19 clinical sequelae of the pathophysiologic responses of hypercoagulability and thromboinflammation associated with acute infection. The acute lung injury that initially occurs in COVID-19 results from vascular and endothelial damage from viral injury and pathophysiologic responses that produce the COVID-19-associated coagulopathy. Clinicians should continue to focus on the vascular endothelial injury that occurs and evaluate potential therapeutic interventions that may benefit those with new infections during the current pandemic as they may also be of benefit for future pathogens that generate similar thromboinflammatory responses. The current Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) studies are important projects that will further define our management strategies. At the time of writing this report, two mRNA vaccines are now being distributed and will hopefully have a major impact on slowing the global spread and subsequent thromboinflammatory injury we see clinically in critically ill patients.

Authors+Show Affiliations

Departments of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, NC, USA.Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.Duke University School of Medicine, Durham, NC, USA.Department of Medicine, Duke University School of Medicine, Durham, NC, USA.Departments of Anesthesiology and Critical Care, Duke University School of Medicine, Durham, NC, USA.Department of Medicine, Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

34288441

Citation

Levy, Jerrold H., et al. "COVID-19: Thrombosis, Thromboinflammation, and Anticoagulation Considerations." International Journal of Laboratory Hematology, vol. 43 Suppl 1, 2021, pp. 29-35.
Levy JH, Iba T, Olson LB, et al. COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations. Int J Lab Hematol. 2021;43 Suppl 1:29-35.
Levy, J. H., Iba, T., Olson, L. B., Corey, K. M., Ghadimi, K., & Connors, J. M. (2021). COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations. International Journal of Laboratory Hematology, 43 Suppl 1, 29-35. https://doi.org/10.1111/ijlh.13500
Levy JH, et al. COVID-19: Thrombosis, Thromboinflammation, and Anticoagulation Considerations. Int J Lab Hematol. 2021;43 Suppl 1:29-35. PubMed PMID: 34288441.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations. AU - Levy,Jerrold H, AU - Iba,Toshiaki, AU - Olson,Lyra B, AU - Corey,Kristen M, AU - Ghadimi,Kamrouz, AU - Connors,Jean M, PY - 2021/02/06/revised PY - 2020/12/31/received PY - 2021/02/11/accepted PY - 2021/7/21/entrez PY - 2021/7/22/pubmed PY - 2021/7/31/medline KW - COVID-19 KW - anticoagulant therapy KW - coagulopathy KW - disseminated intravascular coagulation KW - endothelial cell KW - thrombosis SP - 29 EP - 35 JF - International journal of laboratory hematology JO - Int J Lab Hematol VL - 43 Suppl 1 N2 - Vascular endothelial injury is a hallmark of acute infection at both the microvascular and macrovascular levels. The hallmark of SARS-CoV-2 infection is the current COVID-19 clinical sequelae of the pathophysiologic responses of hypercoagulability and thromboinflammation associated with acute infection. The acute lung injury that initially occurs in COVID-19 results from vascular and endothelial damage from viral injury and pathophysiologic responses that produce the COVID-19-associated coagulopathy. Clinicians should continue to focus on the vascular endothelial injury that occurs and evaluate potential therapeutic interventions that may benefit those with new infections during the current pandemic as they may also be of benefit for future pathogens that generate similar thromboinflammatory responses. The current Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) studies are important projects that will further define our management strategies. At the time of writing this report, two mRNA vaccines are now being distributed and will hopefully have a major impact on slowing the global spread and subsequent thromboinflammatory injury we see clinically in critically ill patients. SN - 1751-553X UR - https://www.unboundmedicine.com/medline/citation/34288441/COVID-19:_Thrombosis,_thromboinflammation,_and_anticoagulation_considerations. L2 - https://doi.org/10.1111/ijlh.13500 DB - PRIME DP - Unbound Medicine ER -